Clinical Trial Update: Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab [Phase 2]

View source ↗

Summary

Phase 2 trial update for GELLC-7 protocol evaluating iBrutinib followed by consolidation with ofatumumab in Chronic Lymphocytic Leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Ibrutinib (ibrutinib)
• Ofatumumab (ofatumumab)

Snippet

Sponsor: PETHEMA Foundation | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: UNKNOWN